Insmed Inc.
Insmed Discontinues Brensocatib Development for HS After Phase 2b Study Fails to Meet Endpoints
Summary
On April 7, 2026, Insmed Incorporated announced that its Phase 2b CEDAR study of brensocatib in patients with moderate to severe hidradenitis suppurativa (HS) did not meet its primary or secondary efficacy endpoints. The study, which enrolled 214 patients globally, showed a 45.5% and 40.3% reduction in abscess and inflammatory nodule count for the 10 mg and 40 mg brensocatib arms, respectively, compared to a 57.1% reduction in the placebo arm. Despite the drug being well tolerated with no new safety signals, Insmed will discontinue the development program for brensocatib in HS and plans to present the data at a future congress.
Profitelligence Alerts
Get alerts for INSM
Be first to know when Insmed Inc. files with the SEC.
Filing Categories
Advertisement
About Insmed Inc.
Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.
Official SEC Documents
Advertisement